Advent leads race to buy US pharma research firm inVentiv for close to $4b

Advent leads race to buy US pharma research firm inVentiv for close to $4b

Private equity firm Advent International is in advanced talks to acquire inVentivGroup Holdings in a deal that could value the U.S. pharmaceutical research firm at close to $4 billion, including debt, people familiar with the matter said on Sunday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter